AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast cancer study, potentially throwing a wrench into its ongoing …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Safe Supply Streaming Co. Ltd. (“Safe Supply” or the “Company”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to announce that they have received
The long-term effectiveness of four school-based, online interventions for preventing mental health and substance use.
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS